$3.63
2.42% today
Nasdaq, Apr 04, 07:19 pm CET
ISIN
US23285D1090
Symbol
CTKB

Cytek BioSciences Inc Target price 2025 - Analyst rating & recommendation

Cytek BioSciences Inc Classifications & Recommendation:

Buy
50%
Hold
33%
Sell
17%

Cytek BioSciences Inc Price Target

Target Price $6.90
Price $3.72
Potential
Number of Estimates 5
5 Analysts have issued a price target Cytek BioSciences Inc 2026 . The average Cytek BioSciences Inc target price is $6.90. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 6 analysts: 3 Analysts recommend Cytek BioSciences Inc to buy, 2 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Cytek BioSciences Inc stock has an average upside potential 2026 of . Most analysts recommend the Cytek BioSciences Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 200.45 206.56
3.85% 3.05%
EBITDA Margin -6.30% 11.63%
28.96% 284.58%
Net Margin -3.22% -3.54%
46.50% 9.84%

6 Analysts have issued a sales forecast Cytek BioSciences Inc 2025 . The average Cytek BioSciences Inc sales estimate is

$207m
Unlock
. This is
3.05% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$208m 3.76%
Unlock
, the lowest is
$204m 1.97%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $200m 3.85%
2025
$207m 3.05%
Unlock
2026
$224m 8.57%
Unlock
2027
$255m 13.54%
Unlock

4 Analysts have issued an Cytek BioSciences Inc EBITDA forecast 2025. The average Cytek BioSciences Inc EBITDA estimate is

$24.0m
Unlock
. This is
290.25% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$34.3m 371.65%
Unlock
, the lowest is
$17.7m 240.03%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-12.6m 26.23%
2025
$24.0m 290.25%
Unlock
2026
$32.4m 34.94%
Unlock
2027
$52.9m 63.18%
Unlock

EBITDA Margin

2024 -6.30% 28.96%
2025
11.63% 284.58%
Unlock
2026
14.46% 24.33%
Unlock
2027
20.78% 43.71%
Unlock

3 Cytek BioSciences Inc Analysts have issued a net profit forecast 2025. The average Cytek BioSciences Inc net profit estimate is

$-7.3m
Unlock
. This is
41.63% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-5.2m 0.03%
Unlock
, the lowest is
$-9.0m 74.91%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-6.5m 44.44%
2025
$-7.3m 13.30%
Unlock
2026
$-4.3m 41.12%
Unlock
2027
$1.3m 129.93%
Unlock

Net Margin

2024 -3.22% 46.50%
2025
-3.54% 9.84%
Unlock
2026
-1.92% 45.76%
Unlock
2027
0.51% 126.56%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.05 -0.06
44.44% 20.00%
P/E negative
EV/Sales 1.10

3 Analysts have issued a Cytek BioSciences Inc forecast for earnings per share. The average Cytek BioSciences Inc EPS is

$-0.06
Unlock
. This is
50.00% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.04 0.00%
Unlock
, the lowest is
$-0.07 75.00%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.05 44.44%
2025
$-0.06 20.00%
Unlock
2026
$-0.03 50.00%
Unlock
2027
$0.01 133.33%
Unlock

P/E ratio

Current -83.04 8.66%
2025
-65.65 20.94%
Unlock
2026
-111.60 69.99%
Unlock
2027
372.00 433.33%
Unlock

Based on analysts' sales estimates for 2025, the Cytek BioSciences Inc stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.13 66.37%
2025
1.10 3.01%
Unlock
2026
1.01 7.89%
Unlock
2027
0.89 11.93%
Unlock

P/S ratio

Current 2.38 47.73%
2025
2.31 2.96%
Unlock
2026
2.12 7.90%
Unlock
2027
1.87 11.93%
Unlock

Current Cytek BioSciences Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Stephens & Co.
Locked
Locked
Locked Mar 19 2025
Piper Sandler
Locked
Locked
Locked Mar 04 2025
Piper Sandler
Locked
Locked
Locked Nov 11 2024
Analyst Rating Date
Locked
Stephens & Co.:
Locked
Locked
Mar 19 2025
Locked
Piper Sandler:
Locked
Locked
Mar 04 2025
Locked
Piper Sandler:
Locked
Locked
Nov 11 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today